High-resolution detection and mapping of genomic DNA alterations in neuroblastoma

Yael P. Mosse, Joel Greshock, Adam Margolin, Tara Naylor, Kristina Cole, Deepa Khazi, George Hii, Cynthia Winter, Syed Shahzad, Muhammad Usman Asziz, Jaclyn A. Biegel, Barbara L. Weber, John M. Maris

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

We used array-based comparative genomic hybridization (aCGH) to measure genomic copy number alterations (CNAs) in 42 neuroblastoma cell lines with known 1p36.3, 2p24 (MYCN), 11q23, and 17q23 allelic status. All cell lines showed CNAs, with an average of 22.0% of the genome of each sample showing evidence of gain (11.6%) or loss (10.4%). MYCN amplification was detected in 81% of cell lines, but other regions with high-level genomic amplification were observed only rarely. Gain of 17q material was present in 75% of the samples, and four discrete genomic regions at 17q23.2-17q25.3 were defined. Novel regions of gain were identified, including a 2.6-Mb subtelomeric region at 5p that includes the telomerase reverse transcriptase gene (TERT), which was found in 45% of the cell lines. Hemizygous deletions were noted at 1p36.23-1p36.32 and 11q23.3-11q25 in 60% and 36%, respectively, of the samples, with other frequent (>25%) regions of deletion localized to 1p32.1, 3p21.31-3p22.1, 5q35.2-5q35.3, 7q31.2, 7q34, 9q22.3-9q24.1, 10q26.11-10q26.12, 16q23.1-16q24.3, 18q21.32-18q23, and 20p11.21-20p11.23. A smallest region of overlap (SRO) for CNAs was mapped across all experiments and in each case was consistent with or refined the published data. A single cell line showed a homozygous deletion at 3p22.3, which was verified, and this location was refined by FISH and PCR. There was outstanding concordance of aCGH with PCR-based CNA detection methods. Several potential cooperating loci were identified, including deletion of 11q23-25, which was highly associated with both regional gain and loss at multiple chromosomal loci but was inversely correlated with the deletion of 1p36. Taking all of this together indicates that aCGH can accurately measure CNAs in the neuroblastoma genome and facilitate gene discovery efforts by high-throughput refinement of candidate loci. Supplementary material for this article can be found on the Genes, Chromosomes and Cancer website at http://www.interscience.wiley.com/ jpages/1045-2257/suppmat/index.html.

Original languageEnglish (US)
Pages (from-to)390-403
Number of pages14
JournalGenes Chromosomes and Cancer
Volume43
Issue number4
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Neuroblastoma
Comparative Genomic Hybridization
Cell Line
DNA
Genome
Polymerase Chain Reaction
Neoplasm Genes
Telomerase
Genetic Association Studies
Chromosomes
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Mosse, Y. P., Greshock, J., Margolin, A., Naylor, T., Cole, K., Khazi, D., ... Maris, J. M. (2005). High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes and Cancer, 43(4), 390-403. https://doi.org/10.1002/gcc.20198

High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. / Mosse, Yael P.; Greshock, Joel; Margolin, Adam; Naylor, Tara; Cole, Kristina; Khazi, Deepa; Hii, George; Winter, Cynthia; Shahzad, Syed; Asziz, Muhammad Usman; Biegel, Jaclyn A.; Weber, Barbara L.; Maris, John M.

In: Genes Chromosomes and Cancer, Vol. 43, No. 4, 08.2005, p. 390-403.

Research output: Contribution to journalArticle

Mosse, YP, Greshock, J, Margolin, A, Naylor, T, Cole, K, Khazi, D, Hii, G, Winter, C, Shahzad, S, Asziz, MU, Biegel, JA, Weber, BL & Maris, JM 2005, 'High-resolution detection and mapping of genomic DNA alterations in neuroblastoma', Genes Chromosomes and Cancer, vol. 43, no. 4, pp. 390-403. https://doi.org/10.1002/gcc.20198
Mosse, Yael P. ; Greshock, Joel ; Margolin, Adam ; Naylor, Tara ; Cole, Kristina ; Khazi, Deepa ; Hii, George ; Winter, Cynthia ; Shahzad, Syed ; Asziz, Muhammad Usman ; Biegel, Jaclyn A. ; Weber, Barbara L. ; Maris, John M. / High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. In: Genes Chromosomes and Cancer. 2005 ; Vol. 43, No. 4. pp. 390-403.
@article{16cf8b5f049d443ab77384eeb7134bc7,
title = "High-resolution detection and mapping of genomic DNA alterations in neuroblastoma",
abstract = "We used array-based comparative genomic hybridization (aCGH) to measure genomic copy number alterations (CNAs) in 42 neuroblastoma cell lines with known 1p36.3, 2p24 (MYCN), 11q23, and 17q23 allelic status. All cell lines showed CNAs, with an average of 22.0{\%} of the genome of each sample showing evidence of gain (11.6{\%}) or loss (10.4{\%}). MYCN amplification was detected in 81{\%} of cell lines, but other regions with high-level genomic amplification were observed only rarely. Gain of 17q material was present in 75{\%} of the samples, and four discrete genomic regions at 17q23.2-17q25.3 were defined. Novel regions of gain were identified, including a 2.6-Mb subtelomeric region at 5p that includes the telomerase reverse transcriptase gene (TERT), which was found in 45{\%} of the cell lines. Hemizygous deletions were noted at 1p36.23-1p36.32 and 11q23.3-11q25 in 60{\%} and 36{\%}, respectively, of the samples, with other frequent (>25{\%}) regions of deletion localized to 1p32.1, 3p21.31-3p22.1, 5q35.2-5q35.3, 7q31.2, 7q34, 9q22.3-9q24.1, 10q26.11-10q26.12, 16q23.1-16q24.3, 18q21.32-18q23, and 20p11.21-20p11.23. A smallest region of overlap (SRO) for CNAs was mapped across all experiments and in each case was consistent with or refined the published data. A single cell line showed a homozygous deletion at 3p22.3, which was verified, and this location was refined by FISH and PCR. There was outstanding concordance of aCGH with PCR-based CNA detection methods. Several potential cooperating loci were identified, including deletion of 11q23-25, which was highly associated with both regional gain and loss at multiple chromosomal loci but was inversely correlated with the deletion of 1p36. Taking all of this together indicates that aCGH can accurately measure CNAs in the neuroblastoma genome and facilitate gene discovery efforts by high-throughput refinement of candidate loci. Supplementary material for this article can be found on the Genes, Chromosomes and Cancer website at http://www.interscience.wiley.com/ jpages/1045-2257/suppmat/index.html.",
author = "Mosse, {Yael P.} and Joel Greshock and Adam Margolin and Tara Naylor and Kristina Cole and Deepa Khazi and George Hii and Cynthia Winter and Syed Shahzad and Asziz, {Muhammad Usman} and Biegel, {Jaclyn A.} and Weber, {Barbara L.} and Maris, {John M.}",
year = "2005",
month = "8",
doi = "10.1002/gcc.20198",
language = "English (US)",
volume = "43",
pages = "390--403",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - High-resolution detection and mapping of genomic DNA alterations in neuroblastoma

AU - Mosse, Yael P.

AU - Greshock, Joel

AU - Margolin, Adam

AU - Naylor, Tara

AU - Cole, Kristina

AU - Khazi, Deepa

AU - Hii, George

AU - Winter, Cynthia

AU - Shahzad, Syed

AU - Asziz, Muhammad Usman

AU - Biegel, Jaclyn A.

AU - Weber, Barbara L.

AU - Maris, John M.

PY - 2005/8

Y1 - 2005/8

N2 - We used array-based comparative genomic hybridization (aCGH) to measure genomic copy number alterations (CNAs) in 42 neuroblastoma cell lines with known 1p36.3, 2p24 (MYCN), 11q23, and 17q23 allelic status. All cell lines showed CNAs, with an average of 22.0% of the genome of each sample showing evidence of gain (11.6%) or loss (10.4%). MYCN amplification was detected in 81% of cell lines, but other regions with high-level genomic amplification were observed only rarely. Gain of 17q material was present in 75% of the samples, and four discrete genomic regions at 17q23.2-17q25.3 were defined. Novel regions of gain were identified, including a 2.6-Mb subtelomeric region at 5p that includes the telomerase reverse transcriptase gene (TERT), which was found in 45% of the cell lines. Hemizygous deletions were noted at 1p36.23-1p36.32 and 11q23.3-11q25 in 60% and 36%, respectively, of the samples, with other frequent (>25%) regions of deletion localized to 1p32.1, 3p21.31-3p22.1, 5q35.2-5q35.3, 7q31.2, 7q34, 9q22.3-9q24.1, 10q26.11-10q26.12, 16q23.1-16q24.3, 18q21.32-18q23, and 20p11.21-20p11.23. A smallest region of overlap (SRO) for CNAs was mapped across all experiments and in each case was consistent with or refined the published data. A single cell line showed a homozygous deletion at 3p22.3, which was verified, and this location was refined by FISH and PCR. There was outstanding concordance of aCGH with PCR-based CNA detection methods. Several potential cooperating loci were identified, including deletion of 11q23-25, which was highly associated with both regional gain and loss at multiple chromosomal loci but was inversely correlated with the deletion of 1p36. Taking all of this together indicates that aCGH can accurately measure CNAs in the neuroblastoma genome and facilitate gene discovery efforts by high-throughput refinement of candidate loci. Supplementary material for this article can be found on the Genes, Chromosomes and Cancer website at http://www.interscience.wiley.com/ jpages/1045-2257/suppmat/index.html.

AB - We used array-based comparative genomic hybridization (aCGH) to measure genomic copy number alterations (CNAs) in 42 neuroblastoma cell lines with known 1p36.3, 2p24 (MYCN), 11q23, and 17q23 allelic status. All cell lines showed CNAs, with an average of 22.0% of the genome of each sample showing evidence of gain (11.6%) or loss (10.4%). MYCN amplification was detected in 81% of cell lines, but other regions with high-level genomic amplification were observed only rarely. Gain of 17q material was present in 75% of the samples, and four discrete genomic regions at 17q23.2-17q25.3 were defined. Novel regions of gain were identified, including a 2.6-Mb subtelomeric region at 5p that includes the telomerase reverse transcriptase gene (TERT), which was found in 45% of the cell lines. Hemizygous deletions were noted at 1p36.23-1p36.32 and 11q23.3-11q25 in 60% and 36%, respectively, of the samples, with other frequent (>25%) regions of deletion localized to 1p32.1, 3p21.31-3p22.1, 5q35.2-5q35.3, 7q31.2, 7q34, 9q22.3-9q24.1, 10q26.11-10q26.12, 16q23.1-16q24.3, 18q21.32-18q23, and 20p11.21-20p11.23. A smallest region of overlap (SRO) for CNAs was mapped across all experiments and in each case was consistent with or refined the published data. A single cell line showed a homozygous deletion at 3p22.3, which was verified, and this location was refined by FISH and PCR. There was outstanding concordance of aCGH with PCR-based CNA detection methods. Several potential cooperating loci were identified, including deletion of 11q23-25, which was highly associated with both regional gain and loss at multiple chromosomal loci but was inversely correlated with the deletion of 1p36. Taking all of this together indicates that aCGH can accurately measure CNAs in the neuroblastoma genome and facilitate gene discovery efforts by high-throughput refinement of candidate loci. Supplementary material for this article can be found on the Genes, Chromosomes and Cancer website at http://www.interscience.wiley.com/ jpages/1045-2257/suppmat/index.html.

UR - http://www.scopus.com/inward/record.url?scp=21744443423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744443423&partnerID=8YFLogxK

U2 - 10.1002/gcc.20198

DO - 10.1002/gcc.20198

M3 - Article

VL - 43

SP - 390

EP - 403

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 4

ER -